Last reviewed · How we verify
Ketoconazole, Hydrocortisone and Dutasteride
Ketoconazole is an antifungal that inhibits lanosterol 14α-demethylase, Dutasteride is a 5α-reductase inhibitor, and Hydrocortisone is a corticosteroid that acts as a glucocorticoid receptor agonist.
Ketoconazole is an antifungal that inhibits lanosterol 14α-demethylase, Dutasteride is a 5α-reductase inhibitor, and Hydrocortisone is a corticosteroid that acts as a glucocorticoid receptor agonist. Used for Fungal infections, Benign prostatic hyperplasia, Severe asthma.
At a glance
| Generic name | Ketoconazole, Hydrocortisone and Dutasteride |
|---|---|
| Also known as | Dutasteride=Avodart |
| Sponsor | Beth Israel Deaconess Medical Center |
| Drug class | Antifungal, 5α-reductase inhibitor, Corticosteroid |
| Target | Lanosterol 14α-demethylase, 5α-reductase, Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease, Dermatology, Oncology |
| Phase | Phase 2 |
Mechanism of action
Ketoconazole works by inhibiting the enzyme lanosterol 14α-demethylase, which is involved in the biosynthesis of ergosterol. Dutasteride inhibits the conversion of testosterone to dihydrotestosterone by blocking the 5α-reductase enzymes. Hydrocortisone exerts its effects by binding to the glucocorticoid receptor, which then translocates to the nucleus and regulates gene expression.
Approved indications
- Fungal infections
- Benign prostatic hyperplasia
- Severe asthma
Common side effects
- Hepatotoxicity
- Gynecomastia
- Cushing's syndrome
Key clinical trials
- Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer (PHASE1, PHASE2)
- Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer (PHASE2)
- Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: